201 related articles for article (PubMed ID: 24492302)
1. Evaluation of human pancreatic RNase as effector molecule in a therapeutic antibody platform.
Schirrmann T; Frenzel A; Linden L; Stelte-Ludwig B; Willuda J; Harrenga A; Dübel S; Müller-Tiemann B; Trautwein M
MAbs; 2014; 6(2):367-80. PubMed ID: 24492302
[TBL] [Abstract][Full Text] [Related]
2. Antibody fusion proteins with human ribonucleases 1 to 8.
Wezler X; Dübel S; Schirrmann T
Hum Antibodies; 2018; 26(4):177-192. PubMed ID: 29689715
[TBL] [Abstract][Full Text] [Related]
3. Endocytotic internalization as a crucial factor for the cytotoxicity of ribonucleases.
Leich F; Stöhr N; Rietz A; Ulbrich-Hofmann R; Arnold U
J Biol Chem; 2007 Sep; 282(38):27640-6. PubMed ID: 17635931
[TBL] [Abstract][Full Text] [Related]
4. A novel fully human antitumor immunoRNase resistant to the RNase inhibitor.
Riccio G; D'Avino C; Raines RT; De Lorenzo C
Protein Eng Des Sel; 2013 Mar; 26(3):243-8. PubMed ID: 23232187
[TBL] [Abstract][Full Text] [Related]
5. Refined immunoRNases for the efficient targeting and selective killing of tumour cells: A novel strategy.
Nassiri M; Behnam-Rasouli R; Vakili-Azghandi M; Gopalan V; Dolati P; Nourmohammadi R
Life Sci; 2022 Jan; 289():120222. PubMed ID: 34902436
[TBL] [Abstract][Full Text] [Related]
6. From immunotoxins to immunoRNases.
De Lorenzo C; D'Alessio G
Curr Pharm Biotechnol; 2008 Jun; 9(3):210-4. PubMed ID: 18673286
[TBL] [Abstract][Full Text] [Related]
7. Cloning and cytotoxicity of a human pancreatic RNase immunofusion.
Zewe M; Rybak SM; Dübel S; Coy JF; Welschof M; Newton DL; Little M
Immunotechnology; 1997 Jun; 3(2):127-36. PubMed ID: 9237097
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapeutic RNases (ImmunoRNases).
Schirrmann T; Krauss J; Arndt MA; Rybak SM; Dübel S
Expert Opin Biol Ther; 2009 Jan; 9(1):79-95. PubMed ID: 19063695
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxicity of human RNase-based immunotoxins requires cytosolic access and resistance to ribonuclease inhibition.
Erickson HA; Jund MD; Pennell CA
Protein Eng Des Sel; 2006 Jan; 19(1):37-45. PubMed ID: 16243897
[TBL] [Abstract][Full Text] [Related]
10. Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells.
D'Avino C; Paciello R; Riccio G; Coppola C; Laccetti P; Maurea N; Raines RT; De Lorenzo C
Protein Eng Des Sel; 2014 Mar; 27(3):83-8. PubMed ID: 24421342
[TBL] [Abstract][Full Text] [Related]
11. A novel human antitumor dimeric immunoRNase.
Riccio G; Borriello M; D'Alessio G; De Lorenzo C
J Immunother; 2008 Jun; 31(5):440-5. PubMed ID: 18463541
[TBL] [Abstract][Full Text] [Related]
12. Biological Activities of Secretory RNases: Focus on Their Oligomerization to Design Antitumor Drugs.
Gotte G; Menegazzi M
Front Immunol; 2019; 10():2626. PubMed ID: 31849926
[TBL] [Abstract][Full Text] [Related]
13. Rational immunotherapy with ribonuclease chimeras. An approach toward humanizing immunotoxins.
Rybak SM; Hoogenboom HR; Newton DL; Raus JC; Youle RJ
Cell Biophys; 1992; 21(1-3):121-38. PubMed ID: 1285324
[TBL] [Abstract][Full Text] [Related]
14. RNase 3 (ECP) is an extraordinarily stable protein among human pancreatic-type RNases.
Maeda T; Mahara K; Kitazoe M; Futami J; Takidani A; Kosaka M; Tada H; Seno M; Yamada H
J Biochem; 2002 Nov; 132(5):737-42. PubMed ID: 12417023
[TBL] [Abstract][Full Text] [Related]
15. Human antibody RNase fusion protein targeting CD30+ lymphomas.
Menzel C; Schirrmann T; Konthur Z; Jostock T; Dübel S
Blood; 2008 Apr; 111(7):3830-7. PubMed ID: 18230757
[TBL] [Abstract][Full Text] [Related]
16. Role of the N terminus in RNase A homologues: differences in catalytic activity, ribonuclease inhibitor interaction and cytotoxicity.
Boix E; Wu Y; Vasandani VM; Saxena SK; Ardelt W; Ladner J; Youle RJ
J Mol Biol; 1996 Apr; 257(5):992-1007. PubMed ID: 8632481
[TBL] [Abstract][Full Text] [Related]
17. Ribonuclease and ribonuclease inhibitor in the human pancreas.
Kiyohara H; Menjo M
Gastroenterol Jpn; 1983 Jun; 18(3):252-4. PubMed ID: 6307804
[TBL] [Abstract][Full Text] [Related]
18. Catalytic diversity of polyclonal RNA-hydrolyzing IgG antibodies from the sera of patients with systemic lupus erythematosus.
Andrievskaya OA; Buneva VN; Baranovskii AG; Gal'vita AV; Benzo ES; Naumov VA; Nevinsky GA
Immunol Lett; 2002 May; 81(3):191-8. PubMed ID: 11947924
[TBL] [Abstract][Full Text] [Related]
19. A novel fully human antitumour immunoRNase targeting ErbB2-positive tumours.
Borriello M; Laccetti P; Terrazzano G; D'Alessio G; De Lorenzo C
Br J Cancer; 2011 May; 104(11):1716-23. PubMed ID: 21559015
[TBL] [Abstract][Full Text] [Related]
20. Engineering Human Pancreatic RNase 1 as an Immunotherapeutic Agent for Cancer Therapy Through Computational and Experimental Studies.
Nassiri M; Ghovvati S; Gharouni M; Tahmoorespur M; Bahrami AR; Dehghani H
Protein J; 2024 Apr; 43(2):316-332. PubMed ID: 38145445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
